Background and Purpose-Cerebral microhemorrhages (MHs) are common among patients presenting with acute ischemic stroke and may predict both subsequent ischemic and hemorrhagic strokes. Methods-We prospectively studied patients with and without MHs presenting within 12 hours of their ischemic stroke or transient ischemic attack (TIA). A magnetic resonance (MR) scan was performed within 24 hours of symptom(s) onset. The primary outcome was disabling or fatal stroke at 18 months. Key Words: cerebral infarction Ⅲ intracerebral hemorrhage Ⅲ magnetic resonance imaging T he prevalence of microhemorrhage (MH) varies between 18% and 62% in patients with acute ischemic stroke. 1-3 MH may be a risk factor of subsequent intracerebral hemorrhage (ICH) and ischemic stroke among patients presenting with acute ischemic stroke. [3] [4] [5] [6] The aim of our study was to determine the risk of disabling or fatal stroke at 18 months in patients presenting with acute stroke or transient ischemic attack (TIA), with and without MH on magnetic resonance (MR).
T he prevalence of microhemorrhage (MH) varies between 18% and 62% in patients with acute ischemic stroke. [1] [2] [3] MH may be a risk factor of subsequent intracerebral hemorrhage (ICH) and ischemic stroke among patients presenting with acute ischemic stroke. [3] [4] [5] [6] The aim of our study was to determine the risk of disabling or fatal stroke at 18 months in patients presenting with acute stroke or transient ischemic attack (TIA), with and without MH on magnetic resonance (MR).
Patients and Methods

Patient Selection
The current study represents a subgroup analysis from a peerreviewed, ongoing, prospective cohort study evaluating neurovascular imaging techniques (MR, computed tomography [CT] , and transcranial Doppler) for predicting clinical outcome and recurrent events in patients presenting early after ischemic stroke or TIA, the VISION study (Vascular Imaging of acute Stroke for Identifying predictors of clinical Outcome and recurrent ischemic eveNts), of which some results were published previously. 7 Patients were eligible for VISION if they had an acute ischemic stroke or TIA (speech or motor) within the previous 12 hours and had a premorbid modified Rankin Scale (mRS) 8 score Յ3. To exclude patients with other neurological diagnoses (migraine, seizure, etc), only TIA patients with symptoms consisting of aphasia or hemiparesis lasting Ͼ5 minutes were included. Patients with persisting neurological symptoms compatible with ischemic stroke were eligible, even if these symptoms were not aphasia or hemiparesis. Exclusion criteria were: CT scan evidence of tumor or hemorrhage, classic migraine features (fortification spectra, typical sensory march), hypoglycemia (serum glucose Ͻ3 mmol/L), and serious comorbid illness with an unlikely chance of 3-month survival. Baseline demographic and clinical data were prospectively collected. All participants provided written informed consent. If patients had an impaired consciousness, a surrogate's consent was obtained. This study was approved by the local ethics review committee.
Imaging
MRI was performed as soon as possible and within 24 hours of symptom(s) onset. MRI studies were done with a 3-T MRI system (Signa; GE Medical Systems) equipped with high-speed gradients (40-mT/m peak strength; 184 s rise time). All imaging was performed using a standard quadrature head coil. The protocol included sagittal, axial, and coronal T1 (3- 512ϫ512]; receiver bandwidth Ϯ12.5 kHz; slice thicknessϭ2.0 mm; 32 slices per slab; 2 slabs acquired; acquisition timeϭ3 minutes 11 seconds), diffusion-weighted imaging (bϭ1000; oblique axial; TEϭ73.2 ms; TRϭ7000 ms; FOVϭ32ϫ19.2 cm; PhaseFovϭ0.6; 192ϫ192 acquisition matrix reconstructed to 256ϫ256; acquisition time of 56 s, receiver bandwidth Ϯ154 kHz; slice thickness/gapϭ5.0 mm/ 2.0 mm, 19 slices), gadolinium bolus-tracking perfusion-weighted echo-planar imaging (PW EPI; oblique axial; flip angleϭ45°; TEϭ45 ms; TRϭ1850 ms; FOVϭ32ϫ19.2 cm; PhaseFovϭ0.6; 160ϫ160 acquisition matrix [reconstructed to 256ϫ256]; receiver bandwidth Ϯ156.25 kHz; slice thickness/gapϭ5.0 mm/2.0 mm; 19 slices; acquisition timeϭ1 minute 18 seconds) or gradient echo (GRE) sequences (oblique axial; TEϭ20 ms; TRϭ500 ms; flip angle of 18°; FOVϭ24ϫ24 cm; PhaseFovϭ0.6; slice thisckness/ gapϭ5.0/2.0 mm; 19 slices; receiver bandwidth Ϯ20.83 kHz; 256ϫ224 acquisition matrix; acquisition time of 1 minute 8 s). GRE sequences were not done routinely before December 2003, but PW EPI was already included in the protocol. All scans were reviewed from a designated work station by a neuroradiologist with expertise in stroke imaging who was blinded to the clinical data. A stroke neurologist blinded to clinical data also reviewed all CT scans and MRI. MHs were defined as small regions of hypointense signal on GRE sequences or on the first 12 T2* PW EPI images obtained before gadolinium contrast arrival. Subsequent perfusion-weighted images were not considered for the identification of MHs. Symmetric signal loss in the globus pallidum was interpreted as calcification. All head CT scan were also reviewed to exclude basal ganglia calcifications. Circular flow void artifacts in the sulci or surface of the brain were interpreted as attributable to blood vessels. White matter disease (leukoaraiosis) was classified as absent, punctate, early confluent, or confluent abnormalities on FLAIR sequences. 9, 10 Patients were classified as having MHs absent or present.
Patient Outcomes
Each patient had a complete neurological evaluation including a National Institutes of Health Stroke Scale (NIHSS) 11 score and an mRS score at baseline and at 3 months. The index event was diagnosed as a stroke if the neurological symptoms lasted Ն24 hours and as a TIA if they were of shorter duration. At 3 months, the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 12 classification was used to determine the stroke and TIA etiology. Patients were managed according to best medical care and received secondary prevention as judged appropriate by the treating physician. At 6 months and every 6 months thereafter, the Questionnaire for Verifying Stroke-Free Status (QVSFS) 13 was completed by phone. Patients with positive answers to the QVSFS were assessed in person. A stroke was judged disabling when the mRS score was Ն3.
Statistical Analysis
The primary composite outcome for the present study was disabling or fatal stroke at 18 months after the index event. Secondary outcomes were all strokes and death. The 18-month risks of outcome were derived from product-limit estimates of event-free survival using Cox proportional hazards regression modeling. Cox modeling was used to adjust for differences in patient characteristics between those with and without MH when deriving adjusted risk estimates and for generating predicted event-free survival curves. Differences between proportions were assessed using a 2 test. MH (Table 2) . Stroke severity (NIHSS), stroke subtype, antithrombotic therapy, hypertension, diabetes, and past medical history did not influence outcomes. Age and presence of confluent white matter disease were the only characteristics identified as confounding factors. Even after adjustment for both of these factors, patients with a MH were 2.8ϫ more likely to have a subsequent disabling or fatal stroke (95% CI, 1.1 to 7.3; Pϭ0.036; Table 2; Figure) . Ten patients with MH died: 7 new strokes, 1 congestive heart failure, and 2 severe pneumonias. The causes of deaths were similar among non-MH patients: 6 new strokes, 3 pneumonias, and 1 lung cancer.
Results
An
A majority of new strokes were ischemic: 85.7% (6 of 7) and 94.1% (16 of 17) for the MH and non-MH groups, respectively. Only 1 symptomatic cerebral hemorrhage occurred in each group, including 1 patient with a single MH patient who died after thrombolysis.
Discussion
We showed that the presence of MH is a risk factor for a subsequent disabling or fatal stroke.
In a previous study, the presence of multiple MH predicted recurrence of both ischemic stroke and ICH, but a control group without MH was not used for comparison. 6 Our study is the first to show that patients presenting with an ischemic stroke or TIA and an MH are more likely to have a recurrent disabling or fatal stroke.
Most recurrent strokes were of ischemic origin. It is possible that some MHs represent hemorrhagic transformation of previous ischemic stroke or that MHs reflect vessel fragility, predisposing to subsequent endothelial instability and stroke.
There is a concern among physicians that antithrombotics could be harmful to MH patients. 14 This concern may be overstated. An increased risk of ICH (9.3%) was shown previously in patients with ischemic stroke and MH. 4 The population studied was Asian and could be more prone to ICH. 15 Another group found a 2.9% rate of ICH at follow-up in patients with MH at baseline. 3 The population studied was heterogenous; some patients had previous ischemic stroke or ICH, whereas a majority had no history of either.
Our study has some limitations. First, 55.6% of the MH patients had a solitary lesion. The study was not designed to analyze outcomes according to the number of MHs; too few patients with MHs prevented us from doing a post hoc analysis of outcomes in single versus multiple MHs. Meanwhile, a conservative attitude with antithrombotics is appropriate in patients with numerous MHs. Second, a larger number of patients and a longer follow-up may be required to find a significant increase of symptomatic ICH among MH patients. Third, no patient with or without MHs had previous symptomatic ICH in our study, and these patients may be at higher risk of recurrent ICH. Fourth, although some used EPI for the diagnosis of MHs, it may be less sensitive to MHs than GRE. 16 Contrary to others, we used a 3T MRI. and although it should be more sensitive than a 1.5-T MR for the presence of MH, this remains unproven.
In summary, we showed that the presence of MH is a predictor of subsequent disabling or fatal stroke in a population of ischemic stroke and TIA patients. Crude product-limit estimates of the event-free survival from Cox proportional hazards regression model. Risk estimates from Cox proportional hazards regression model adjusted for age and presence of confluent white matter disease.
P value for testing the statistical significance of the HR. *The ICH rate was 3.3% vs 0.8% in the MHs present and MHs absent groups, respectively (P valueϭ0.31). The risk of ischemic stroke was 20.3% and 8.7%, respectively (P valueϭ0.039).
Freedom from disabling or fatal stroke curves for patients with and without MH(s), adjusted for age and presence of white matter disease. The adjusted 18-month risks of disabling or fatal stroke are shown as percentages on the right-hand side of the curves.
